PDF herunterladen
CC BY 4.0 · AJP Rep 2025; 15(02): e47-e52
DOI: 10.1055/a-2562-1643
Original Article

Adverse Pregnancy Outcomes in Sjogren's Disease Compared to Controls: An Interdisciplinary Approach with Maternal–Fetal Medicine

Lauren Tesoriero
1   Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York
2   NYU Long Island School of Medicine, Mineola, New York
,
Jennifer Kidd
3   Northwell Health New Hyde Park, New York
4   Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Uniondale, Uniondale, New York
5   Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York
,
Julie Piccione
1   Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York
2   NYU Long Island School of Medicine, Mineola, New York
,
Peter Izmirly
6   Division of Rheumatology, NYU Langone Health, New York, New York
7   NYU Grossman School of Medicine New York, New York
,
Meredith Akerman
2   NYU Long Island School of Medicine, Mineola, New York
,
Steven Carsons
1   Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York
2   NYU Long Island School of Medicine, Mineola, New York
,
Patricia Rekawek 
2   NYU Long Island School of Medicine, Mineola, New York
8   Department of Maternal Fetal Medicine, NYU Langone Hospital, Long Island, Mineola, New York
,
Julie Nusbaum
1   Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York
2   NYU Long Island School of Medicine, Mineola, New York
› Institutsangaben Funding This study was approved by our Institutional Review Board, Study Number S23 to 0044.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objectives

Outside of the association of SS-A antibody with congenital heart block, little is known about adverse maternal and neonatal outcomes, in patients with Sjogren's disease (SjD). Our study involved collaboration with maternal–fetal medicine (MFM).

Methods

A retrospective cohort study of pregnant patients: SjD patients were matched 1:3 with non-SjD controls. SjD patients were included by meeting the 2016 ACR/EULAR Criteria or by a rheumatologist diagnosis. Exclusion criteria were concurrent autoimmune disease or related antibodies. A composite of grouped outcomes was utilized and verified by MFM specialists. The primary outcome was adverse pregnancy outcome (APO) between the two groups. Statistical analysis was performed using a two-sample t-test and Fisher's exact test.

Results

48 patients were included: 12 SjD patients and 36 controls. APO was significantly increased in SjD with one preterm birth, one fetal growth restriction, and one limb anomaly; non-SjD had one cardiac anomaly. There were no cases of CHB. SjD patients were more likely to be delivered by cesarean delivery.

Conclusion

There was an increased risk of APO in SjD patients compared with controls. No significant difference in neonatal outcomes was found. We speculate that placental pathology may play a role in pathophysiology and future studies should be performed.

Key Points

  • There was an increased risk of APO in SjD patients compared with controls.

  • No significant difference in neonatal outcomes was found.

  • We speculate that placental pathology may play a role in pathophysiology, prompting future studies.

Keywords

adverse pregnancy outcomes - Sjogren's disease - SS-A - SS-B antibodies - autoimmune disease


Publikationsverlauf

Eingereicht: 07. Januar 2025

Angenommen: 27. Februar 2025

Accepted Manuscript online:
19. März 2025

Artikel online veröffentlicht:
08. April 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Izmirly PM, Buyon JP, Wan I. et al. The incidence and prevalence of adult primary Sjögren's Syndrome in New York County. Arthritis Care Res (Hoboken) 2019; 71 (07) 949-960
    PubMedSuche in Google Scholar
  • 2 Fox RI. Sjögren's syndrome. Lancet 2005; 366 (9482) 321-331
    CrossrefPubMedSuche in Google Scholar
  • 3 Both T, Dalm VA, van Hagen PM, van Daele PL. Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment. Int J Med Sci 2017; 14 (03) 191-200
    PubMedSuche in Google Scholar
  • 4 Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11 (05) 301-312
    CrossrefPubMedSuche in Google Scholar
  • 5 de Frémont GM, Costedoat-Chalumeau N, Lazaro E. et al; GR2 Study Group. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol 2023; 5 (06) e330-e340
    PubMedSuche in Google Scholar
  • 6 Upala S, Yong WC, Sanguankeo A. Association between primary Sjögren's syndrome and pregnancy complications: a systematic review and meta-analysis. Clin Rheumatol 2016; 35 (08) 1949-1955
    PubMedSuche in Google Scholar
  • 7 Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199 (02) 127.e1-127.e6
    CrossrefPubMedSuche in Google Scholar
  • 8 Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001; 10 (02) 91-96
    PubMedSuche in Google Scholar
  • 9 Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obst Gynecol 2003; 101 (06) 1333-1344
    PubMedSuche in Google Scholar
  • 10 Chou AK, Hsieh SC, Su YN. et al. Neonatal and pregnancy outcome in primary antiphospholipid syndrome: a 10-year experience in one medical center. Pediatr Neonatol 2009; 50 (04) 143-146
    PubMedSuche in Google Scholar
  • 11 Kim MY, Guerra MM, Kaplowitz E. et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis 2018; 77 (04) 549-555
    PubMedSuche in Google Scholar
  • 12 Carvalheiras G, Faria R, Braga J, Vasconcelos C. Fetal outcome in autoimmune diseases. Autoimmun Rev 2012; 11 (6–7): A520-A530
    CrossrefPubMedSuche in Google Scholar
  • 13 Castellanos Gutierrez AS, Figueras F, Morales-Prieto DM, Schleußner E, Espinosa G, Baños N. Placental damage in pregnancies with systemic lupus erythematosus: a narrative review. Front Immunol 2022; 13: 941586
    PubMedSuche in Google Scholar